Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:GNLX NASDAQ:IFRX NASDAQ:LITS NASDAQ:NRXP On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGNLXGenelux$2.92-1.0%$2.95$2.29▼$8.53$130.93M0.58211,509 shs145,451 shsIFRXInflaRx$1.69-0.6%$2.03$0.74▼$2.95$122.18M2.441.18 million shs1.20 million shsLITSLite Strategy$0.97-0.7%$0.93$0.69▼$6.00$33.01M0.21362,415 shs97,157 shsNRXPNRx Pharmaceuticals$3.54-2.5%$3.97$1.62▼$5.05$128.25M2.191.12 million shs1.03 million shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGNLXGenelux+2.08%+0.68%+2.68%+16.60%-11.68%IFRXInflaRx-2.30%-6.59%-11.50%+1.80%+89.16%LITSLite Strategy-1.20%-5.19%+11.22%-14.34%+97,649,900.00%NRXPNRx Pharmaceuticals-3.20%-13.16%-2.68%+23.05%+21.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGNLXGenelux$2.92-1.0%$2.95$2.29▼$8.53$130.93M0.58211,509 shs145,451 shsIFRXInflaRx$1.69-0.6%$2.03$0.74▼$2.95$122.18M2.441.18 million shs1.20 million shsLITSLite Strategy$0.97-0.7%$0.93$0.69▼$6.00$33.01M0.21362,415 shs97,157 shsNRXPNRx Pharmaceuticals$3.54-2.5%$3.97$1.62▼$5.05$128.25M2.191.12 million shs1.03 million shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGNLXGenelux+2.08%+0.68%+2.68%+16.60%-11.68%IFRXInflaRx-2.30%-6.59%-11.50%+1.80%+89.16%LITSLite Strategy-1.20%-5.19%+11.22%-14.34%+97,649,900.00%NRXPNRx Pharmaceuticals-3.20%-13.16%-2.68%+23.05%+21.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGNLXGenelux 2.50Moderate Buy$18.00516.44% UpsideIFRXInflaRx 2.71Moderate Buy$7.00314.20% UpsideLITSLite Strategy 1.00SellN/AN/ANRXPNRx Pharmaceuticals 2.50Moderate Buy$38.25980.51% UpsideCurrent Analyst Ratings BreakdownLatest LITS, GNLX, NRXP, and IFRX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/17/2026GNLXGenelux Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)7/17/2026LITSLite Strategy Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)6/24/2026IFRXInflaRx Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)6/1/2026LITSLite Strategy Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)5/13/2026IFRXInflaRx Raymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeOutperform ➝ Strong-Buy$7.00 ➝ $9.005/11/2026IFRXInflaRx HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$6.00 ➝ $8.005/11/2026IFRXInflaRx Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$2.00 ➝ $4.005/8/2026NRXPNRx Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)5/5/2026NRXPNRx Pharmaceuticals D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$34.00(Data available from 7/28/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGNLXGenelux$10K13,093.28N/AN/A$0.30 per share9.73IFRXInflaRx$29.33K4,165.39N/AN/A$0.65 per share2.60LITSLite Strategy$65.30M0.51N/AN/AN/A∞NRXPNRx Pharmaceuticals$2.29M55.93N/AN/A($0.54) per share-6.56Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGNLXGenelux-$32.15M-$0.85N/AN/AN/AN/A-174.55%-123.65%8/6/2026 (Estimated)IFRXInflaRx-$51.63M-$0.71N/AN/AN/AN/A-88.30%-65.77%8/6/2026 (Estimated)LITSLite Strategy-$15.94M-$1.60N/AN/AN/AN/A-90.81%-89.33%N/ANRXPNRx Pharmaceuticals-$28.62M-$1.09N/A6.00N/AN/AN/A-202.92%8/17/2026 (Estimated)Latest LITS, GNLX, NRXP, and IFRX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/17/2026Q2 2026NRXPNRx Pharmaceuticals-$0.09N/AN/AN/A$1.75 millionN/A8/6/2026Q2 2026GNLXGenelux-$0.20N/AN/AN/AN/AN/A8/6/2026Q2 2026IFRXInflaRx-$0.08N/AN/AN/A$0.01 millionN/A5/15/2026Q1 2026NRXPNRx Pharmaceuticals-$0.05-$0.04+$0.01-$0.04$19.43 million$1.07 million5/13/2026Q3 2026LITSLite StrategyN/A-$0.66N/A-$0.66N/AN/A5/7/2026Q1 2026GNLXGenelux-$0.18-$0.20-$0.02-$0.20$0.01 millionN/A5/6/2026Q1 2026IFRXInflaRx-$0.17-$0.09+$0.08-$0.09$0.01 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthGNLXGeneluxN/AN/AN/AN/AN/AIFRXInflaRxN/AN/AN/AN/AN/ALITSLite StrategyN/AN/AN/AN/AN/ANRXPNRx PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGNLXGeneluxN/A3.683.68IFRXInflaRxN/A4.164.16LITSLite StrategyN/A11.5311.53NRXPNRx PharmaceuticalsN/A0.290.29Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGNLXGenelux37.33%IFRXInflaRx42.39%LITSLite Strategy52.38%NRXPNRx Pharmaceuticals4.27%Insider OwnershipCompanyInsider OwnershipGNLXGenelux7.50%IFRXInflaRx16.30%LITSLite Strategy1.60%NRXPNRx Pharmaceuticals6.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGNLXGenelux1044.84 million41.48 millionNot OptionableIFRXInflaRx6072.29 million60.51 millionOptionableLITSLite Strategy10034.03 million33.48 millionN/ANRXPNRx Pharmaceuticals236.23 million33.91 millionOptionableLITS, GNLX, NRXP, and IFRX HeadlinesRecent News About These CompaniesNRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Receives Consensus Rating of "Moderate Buy" from BrokeragesJuly 21, 2026 | americanbankingnews.comNRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Receives Consensus Recommendation of "Moderate Buy" from BrokeragesJuly 21, 2026 | marketbeat.comNRx Pharmaceuticals (NASDAQ:NRXP) Shares Up 0.7% - Time to Buy?July 17, 2026 | marketbeat.comIs NRx Pharmaceuticals, Inc. (NRXP) Stock Positioned for Growth Through Depression and PTSD Treatment Innovation?July 15, 2026 | insidermonkey.comNRx Pharmaceuticals Responds to Recent Public Statements Regarding Kadima DisputeJune 25, 2026 | globenewswire.comNRx Pharmaceuticals (Nasdaq: NRXP) Subsidiary HOPE Therapeutics Treats First Patients Using Zeta Surgical's FDA-Cleared Zeta TMS Navigation SystemJune 25, 2026 | globenewswire.comKadima Neuropsychiatry Institute Files Suit Against NRx Pharmaceuticals (NASDAQ: NRXP), Alleging Breach of Contract and Misrepresentation in Connection with AcquisitionJune 24, 2026 | businesswire.comZETA SURGICAL® Announces Successful Treatment of First Patient with Zeta TMS Navigation System at HOPE TherapeuticsJune 23, 2026 | prnewswire.comNRx Pharmaceuticals Announces FDA Grant of Expanded Access Protocol for Use of D-Cycloserine-based NRX-101 for Augmentation of Transcranial Magnetic Stimulation in the ...June 22, 2026 | markets.businessinsider.comNRx Pharmaceuticals Announces FDA Grant of Expanded Access Protocol for Use of D-Cycloserine-based NRX-101 for Augmentation of Transcranial Magnetic Stimulation in the Treatment of DepressionJune 22, 2026 | globenewswire.comNRX Pharmaceuticals Inc (NRXP) Q1 2026 Earnings Call Highlights: Strategic Advances Amid ...June 18, 2026 | finance.yahoo.comNRx Pharmaceuticals (NRXP) Closes Underwritten Public Offering of Common Stock At $3.50 Per ShareJune 10, 2026 | insidermonkey.comNRx Pharmaceuticals (Nasdaq:NRXP) notes presentation by Osmind, Inc. of IV Ketamine Efficacy vs. Nasal esketamine Efficacy at American Society of Clinical Psychopharmacology.June 5, 2026 | globenewswire.comNRx Pharmaceuticals, Inc. Announces Closing of $22.3 Million Public Offering of Common Stock and Including Exercise of the Underwriters’ OptionJune 5, 2026 | markets.businessinsider.comNRx Pharmaceuticals Announces $20 Million Public Stock OfferingJune 4, 2026 | tipranks.comNRx Pharmaceuticals Closes $22.3 Million Public Offering to Support Growth and Development of CNS TherapeuticsJune 4, 2026 | quiverquant.comQNRx Pharmaceuticals, Inc. Announces Closing of $22.3 Million Public Offering of Common Stock and Including Exercise of the Underwriters' OptionJune 4, 2026 | globenewswire.comNRx Pharmaceuticals Plans Underwritten Public Stock OfferingJune 4, 2026 | theglobeandmail.comNRx Pharmaceuticals Prices Public Offering of Common Stock to Raise Approximately $20 MillionJune 3, 2026 | quiverquant.comQNRx Pharmaceuticals, Inc. Announces Pricing of Public Offering of Common StockJune 3, 2026 | globenewswire.comNRx Pharmaceuticals (NRXP) stock fell 19% after hours on Tuesday: Here's whyJune 3, 2026 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeLITS, GNLX, NRXP, and IFRX Company DescriptionsGenelux NASDAQ:GNLX$2.92 -0.03 (-1.02%) Closing price 04:00 PM EasternExtended Trading$2.92 0.00 (0.00%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer. The company is also developing V2ACT Immunotherapy for treating pancreatic cancer. Genelux Corporation has a licensing agreement with ELIAS Animal Health, LLC for V-VET1, a clinical stage animal health product candidate. The company was incorporated in 2001 and is headquartered in Westlake Village, California.InflaRx NASDAQ:IFRX$1.69 -0.01 (-0.59%) Closing price 04:00 PM EasternExtended Trading$1.70 +0.01 (+0.30%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage. The company develops INF904, an oral, small molecule drug candidate for the chronic inflammatory and autoimmune diseases; IFX002 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases; and Gohibic (vilobelimab) for the treatment of COVID-19 and broader ARDS. It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd.; and clinical trial collaboration and supply agreement with Merck & Co. Inc. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany.Lite Strategy NASDAQ:LITS$0.97 -0.01 (-0.67%) Closing price 04:00 PM EasternExtended Trading$0.97 +0.00 (+0.21%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.MEI Pharma, Inc., a late-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor that is in Phase III clinical trial for the treatment of patients with relapsed/refractory follicular lymphoma, as well as in Phase Ib multi-arm trial to treat B-cell malignancies; and Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, which is in Phase Ib clinical trial for acute myeloid leukemia and B-cell malignancies. It also develops ME-344, a mitochondrial inhibitor targeting the oxidative phosphorylation complex that is in Phase I clinical trial for the treatment of human epidermal growth factor receptor 2 negative breast cancer; and Pracinostat, an oral available histone deacetylase inhibitor, which is in Phase II clinical trial to treat patients with myelodysplastic syndrome. MEI Pharma, Inc. has a license, development, and commercialization agreement with Kyowa Kirin Company; a clinical collaboration with BeiGene, Ltd.; a license, development, manufacturing, and commercialization agreement with Helsinn Healthcare SA; and a license agreement with Presage Biosciences, Inc. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma, Inc. was incorporated in 2000 and is headquartered in San Diego, California.NRx Pharmaceuticals NASDAQ:NRXP$3.54 -0.09 (-2.48%) Closing price 04:00 PM EasternExtended Trading$3.53 -0.01 (-0.28%) As of 04:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior. The company has a partnership with Alvogen Inc. and Lotus Pharmaceutical Company; development and manufacturing agreement with Nephron Pharmaceuticals, Inc. and Alcami; license agreement with Apkarian Technologies; development and license agreement with Glytech; license agreement with Sarah Herzog Memorial Hospital. The company was founded in 2015 and is based in Wilmington, Delaware. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Hasbro’s Earnings Beat Shows Why This Is No Longer Just a Toy Story Rambus: Another AI Phoenix Ready to Rise From the Ashes of Correction Amkor Sells Off After Earnings—Why Weak Guidance Isn't the Real Story Nano Nuclear’s Air Force Contract Puts Its Short-Squeeze Setup in Focus Western Digital’s Earnings Will Test Whether Its AI Rally Has More Room 5 Space Stocks Face a Brutal Correction: Which Ones Are Still Buys? Is the Market Mispricing ServiceNow's AI Future? Chips & Clips: Memory Tariffs Rewire Tech Supply Chains Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
